Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Sarah C. Rutherford(NewYork–Presbyterian Hospital), John P. Leonard(New York University), Kami J. Maddocks(The Ohio State University), Robin Joyce(Beth Israel Deaconess Medical Center), Stefan K. Barta(University of Pennsylvania), Ying Yuan(Zhejiang Cancer Hospital), Trisha Ali-Shaw(Cornell University), Nadia Khan(Fox Chase Cancer Center), Nancy L. Bartlett(Washington University in St. Louis), Silvia Senese(University of California, Los Angeles), Jason R. Westin(The University of Texas MD Anderson Cancer Center)
Cited by 27
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k